The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

NACompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

June 7, 2024

Study Completion Date

June 7, 2024

Conditions
MDD
Interventions
DEVICE

Relivion®DP- Active

Relivion®DP- Active stimulation device

DEVICE

Relivion®DP- Sham

Relivion®DP- Sham stimulation device

Trial Locations (13)

21204

Sheppard Prat Health system, Baltimore

27514

University of North Carolina, Department of Psychiatry, Chapel Hill

29425

MUSC Institute of Psychiatry, Charleston

33014

San Marcus Research Clinic, Miami Lakes

33607

K2 Medical Research Tampa, Tampa

55416

University of Minnesota, Minneapolis

60611

Northwestern University, Feinberg School of Medicine, Chicago

77046

Brain Health Consultants and TMS Center, Houston

90024

UCLA Semel Institute for Neuroscience and Behaviour, Los Angeles

92037

Kadima Neuropsychiatry Institute, La Jolla

02906

Butler Hospital/Brown University, Providence

02908

VA Providence Healthcare System, Providence

Unknown

Ichilov Medical Center, Tel Aviv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neurolief Ltd.

INDUSTRY

NCT04279522 - The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD) | Biotech Hunter | Biotech Hunter